BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports

Eur J Cancer. 2019 Nov:121:109-112. doi: 10.1016/j.ejca.2019.08.029. Epub 2019 Sep 27.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Drug Resistance, Neoplasm / genetics*
  • Exons / genetics
  • Female
  • Humans
  • Imidazoles / administration & dosage*
  • MAP Kinase Kinase Kinases / antagonists & inhibitors
  • Male
  • Melanoma / drug therapy*
  • Melanoma / genetics
  • Melanoma / pathology
  • Middle Aged
  • Mutation
  • Neoplasm Metastasis
  • Oximes / administration & dosage*
  • Protein Kinase Inhibitors / administration & dosage
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors
  • Proto-Oncogene Proteins B-raf / genetics*
  • Pyridones / administration & dosage*
  • Pyrimidinones / administration & dosage*
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / genetics
  • Skin Neoplasms / pathology
  • Treatment Outcome

Substances

  • Imidazoles
  • Oximes
  • Protein Kinase Inhibitors
  • Pyridones
  • Pyrimidinones
  • trametinib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • MAP Kinase Kinase Kinases
  • dabrafenib